Excellent quality and fast dispatch
Products arrived well-packaged with COA documentation included. Really appreciate the clear research-only labelling — exactly what I needed for my lab work.
James R.
Sydney, AU
Selective MC4R Agonist (Bremelanotide)
PT-141 Australia
Everything researchers need to know about PT-141 — mechanism, published dosing protocols, side effect profiles, reconstitution, and how to source third-party tested PT-141 in Australia.
Quick facts
- Also known as: Bremelanotide
- Form: Lyophilised powder (>99% purity)
- Variants: 10 mg
- 🇦🇺 3–5 business days
March 2025
Best local supplier I've found
Ordered three times now. HPLC verification results have been consistent each time. The pathway browsing structure makes it much easier to compare compounds.
Sarah K.
Melbourne, AU
Fast shipping, great documentation
Same-day dispatch on my last two orders. The batch COA was easy to locate and the product information pages are genuinely useful for research planning.
Michael T.
Brisbane, AU
Representative of verified researcher feedback.
Overview
What Is PT-141?
PT-141 (Bremelanotide) is a synthetic melanocortin peptide derived from Melanotan II, engineered for selectivity at the MC4R receptor. Unlike PDE5 inhibitors which act peripherally on vascular smooth muscle, PT-141 acts centrally via hypothalamic melanocortin pathways, making it unique for studying CNS-mediated sexual arousal mechanisms.
Also known as Bremelanotide, PT-141 is supplied as a lyophilised research peptide for laboratory use only. Studies demonstrate PT-141 activates MC4R receptors in the hypothalamus, triggering downstream dopaminergic signaling in the medial preoptic area. Unlike Melanotan II, it has minimal MC1R activity (reduced pigmentation effects). Preclinical research shows efficacy in both male and female models of sexual dysfunction.
Mechanism
How PT-141 Works — Research Mechanism
Studies demonstrate PT-141 activates MC4R receptors in the hypothalamus, triggering downstream dopaminergic signaling in the medial preoptic area. Unlike Melanotan II, it has minimal MC1R activity (reduced pigmentation effects). Preclinical research shows efficacy in both male and female models of sexual dysfunction.
- Selective MC4R agonist derived from Melanotan II structure
- Central hypothalamic mechanism — distinct from peripheral PDE5 inhibitors
- Minimal MC1R activity (reduced pigmentation vs Melanotan II)
- Dopaminergic signalling in medial preoptic area in research models
- Efficacy in both male and female sexual dysfunction models
Research reference
PT-141 Dosage — Published Research Protocols
The following reference points are drawn from published research literature. These figures are provided for research reference only and do not constitute dosing recommendations. PT-141 is sold strictly for laboratory research use.
| Protocol tier | Published research detail |
|---|---|
| Research reference | Published literature varies by model and endpoint — consult primary sources for protocol-specific dosing in laboratory settings |
| Administration route | Subcutaneous injection is most common in published peptide research protocols |
| Frequency | Dosing frequency depends on compound half-life and research design — daily to weekly intervals reported in literature |
| Available vial sizes | 10 mg — select based on your laboratory protocol requirements |
| Titration | Many research protocols start at lower doses and escalate to assess receptor response and tolerability in models |
Research use only: FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, injection, or therapeutic use. All products are sold strictly as research chemicals. By purchasing, you confirm you are 18+ and agree to use products solely for legitimate research purposes.
Safety research
PT-141 Side Effects — Research Findings
Side effect profiles documented in published PT-141 research depend on dose, route of administration, and model system. The following are commonly reported findings from research literature — not from personal use contexts.
- Mild nasal irritation when intranasal routes used in published Semax/Selank research
- Injection site reactions for subcutaneous administration routes
- Generally well-tolerated in nootropic peptide literature at research doses
- No significant dependence or withdrawal reported in animal model studies
Handling
Reconstituting PT-141
PT-141 is supplied as a lyophilised powder and must be reconstituted before use in laboratory protocols. Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials. Inject diluent slowly down the inside wall of the vial — do not shake vigorously.
Bacteriostatic water is available from EvoPeak. Store reconstituted peptide at 2–8°C and lyophilised powder at −20°C.
Shop bacteriostatic waterAustralia
How to Get PT-141 in Australia
Researchers in Australia can source PT-141 through EvoPeak — a local supplier offering third-party tested research compounds with batch-specific COA documentation and domestic shipping.
- 1
Browse PT-141 variants (10 mg) on the EvoPeak product page
- 2
Review the certificate of analysis (COA) for HPLC purity and mass spectrometry identity verification
- 3
Select your vial size and add to cart — prices include GST with same-day Australian dispatch
- 4
Receive your order with batch-specific quality documentation for laboratory traceability
Quality Standard
Research compounds need evidence, not guesswork.
Every shopping path leads back to the same core standard: research-use positioning, third-party quality signals, transparent documentation, and careful handling guidance.
HPLC/MS verified
Purity and identity checks support confident compound selection for controlled research.
Endotoxin screened
Quality review extends beyond purity so researchers can evaluate handling risk.
Batch documentation
COA-first product pages keep quality signals close to every purchase decision.
Australia shipped
Local fulfilment keeps delivery predictable for Australian research customers.
FAQ
PT-141 — Common Questions
What is PT-141?
Selective MC4R agonist for sexual function pathway research. PT-141 (Bremelanotide) is a synthetic melanocortin peptide derived from Melanotan II, engineered for selectivity at the MC4R receptor. Unlike PDE5 inhibitors which act peripherally on vascular smooth … It is supplied for laboratory research use only.
What is the PT-141 dosage used in research?
Published research uses varying doses depending on the model and endpoint. EvoPeak supplies 10 mg vials. All dosage information is for research reference only and does not constitute recommendations.
What are the side effects of PT-141?
Side effect profiles in published research depend on dose, route, and model system. Consult primary literature for compound-specific findings. All information is drawn from research contexts, not personal use.
Can I buy PT-141 in Australia?
Yes. EvoPeak supplies research-grade PT-141 to Australian researchers with HPLC/MS verification, batch-specific COA documentation, and domestic shipping. Products are for laboratory research use only.
How do I get PT-141 in Australia?
Order from the EvoPeak shop page, select your vial size, review the COA, and checkout with local Australian fulfilment.
How do I reconstitute PT-141?
PT-141 is supplied as lyophilised powder. Reconstitute with bacteriostatic water, inject diluent slowly down the vial wall without shaking, and store at 2–8°C once reconstituted. Bacteriostatic water is available from EvoPeak.
What purity standard does EvoPeak PT-141 meet?
Every batch undergoes HPLC purity analysis (targeting >99%), mass spectrometry identity verification, and endotoxin screening. Batch-specific COAs are available on the product page.
Is pt-141 peptide the same as Bremelanotide?
PT-141 is also known as Bremelanotide. Both refer to the same research compound supplied by EvoPeak.
Related compounds
Explore related research peptides
Ready to order PT-141?
Third-party HPLC/MS tested with batch-specific COA documentation. Shipped from Australia for laboratory research use only.